Catalent Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Catalent sono diminuiti a un tasso medio annuo di -53.1%, mentre il settore Pharmaceuticals ha visto gli utili crescere a un tasso medio annuo di 1.2%. I ricavi sono cresciuti crescere a un tasso medio annuo di 8.7%.

Informazioni chiave

-53.1%

Tasso di crescita degli utili

-53.0%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	6.0%
Tasso di crescita dei ricavi	8.7%
Rendimento del capitale proprio	-11.7%
Margine netto	-9.3%
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Catalent, Inc.'s (NYSE:CTLT) Share Price Not Quite Adding Up

Aug 30

Are Investors Undervaluing Catalent, Inc. (NYSE:CTLT) By 24%?

Jul 23

Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy

Jun 25

Catalent to make Sarepta Therapeutics' muscle wasting gene therapy under supply deal

Jan 05

An Intrinsic Calculation For Catalent, Inc. (NYSE:CTLT) Suggests It's 27% Undervalued

Dec 27

Humanigen to pay Catalent Pharma $12M to settle supply agreement dispute

Dec 22

Catalent falls after new short call from Glasshouse Research

Dec 08

Catalent Q1 2023 Earnings Preview

Oct 31

These 4 Measures Indicate That Catalent (NYSE:CTLT) Is Using Debt Extensively

Oct 26

Catalent: Charting A Post-Covid Future

Oct 19

Ripartizione dei ricavi e delle spese

Come Catalent guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NYSE:CTLT Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	4,422	-413	981	0
30 Jun 24	4,381	-1,043	935	0
31 Mar 24	4,135	-1,176	897	0
31 Dec 23	4,098	-1,302	863	0
30 Sep 23	4,223	-1,015	839	0
30 Jun 23	4,263	-256	839	0
31 Mar 23	4,495	21	840	0
31 Dec 22	4,731	389	866	0
30 Sep 22	4,799	399	867	0
30 Jun 22	4,802	483	844	0
31 Mar 22	4,703	485	803	0
31 Dec 21	4,483	561	768	0
30 Sep 21	4,177	544	706	0
30 Jun 21	3,998	529	687	0
31 Mar 21	3,757	494	658	0
31 Dec 20	3,465	289	623	0
30 Sep 20	3,275	250	598	0
30 Jun 20	3,094	173	577	0
31 Mar 20	2,872	104	562	1
31 Dec 19	2,729	124	554	2
30 Sep 19	2,631	138	535	3
30 Jun 19	2,518	132	512	0
31 Mar 19	2,478	149	489	4
31 Dec 18	2,488	136	475	5
30 Sep 18	2,471	65	466	5
30 Jun 18	2,463	84	459	6
31 Mar 18	2,395	63	430	7
31 Dec 17	2,300	70	413	7
30 Sep 17	2,177	109	396	7
30 Jun 17	2,075	110	396	7
31 Mar 17	1,991	106	373	7
31 Dec 16	1,896	91	365	7
30 Sep 16	1,867	104	362	8
30 Jun 16	1,848	112	351	8
31 Mar 16	1,826	207	346	10
31 Dec 15	1,835	228	333	10
30 Sep 15	1,836	244	327	11
30 Jun 15	1,831	212	325	12
31 Mar 15	1,840	86	315	14
31 Dec 14	1,847	62	320	15
30 Sep 14	1,832	-3	318	17
30 Jun 14	1,828	19	317	18
31 Mar 14	1,813	2	328	17
31 Dec 13	1,807	-20	326	16

Guadagni di qualità: CTLT al momento non è redditizia.

Margine di profitto in crescita: CTLT al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: CTLT non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 53.1% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di CTLT nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: CTLT non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Pharmaceuticals ( 54.6% ).

Rendimento del capitale proprio

ROE elevato: CTLT ha un Return on Equity negativo ( -11.66% ), in quanto al momento non è redditizio.

Catalent Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Full year 2024 earnings: EPS misses analyst expectations

Catalent, Inc. to Report Q2, 2024 Results on Feb 09, 2024

Catalent, Inc. to Report Q1, 2024 Results on Nov 15, 2023

Full year 2023 earnings: EPS misses analyst expectations

Catalent, Inc. to Report Q4, 2023 Results on Aug 29, 2023

Catalent, Inc. Reports Impairment Results for the Quarter Ended March 31, 2023

Recent updates

Catalent, Inc. announced delayed annual 10-K filing

Full year 2024 earnings: EPS misses analyst expectations

Catalent, Inc.'s (NYSE:CTLT) Share Price Not Quite Adding Up

New minor risk - Insider selling

President recently sold US$534k worth of stock

President notifies of intention to sell stock

Are Investors Undervaluing Catalent, Inc. (NYSE:CTLT) By 24%?

Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy

Now 20% undervalued after recent price drop

Price target increased by 15% to US$63.50

Insufficient new directors

Catalent, Inc. announced delayed 10-Q filing

Insufficient new directors

Catalent - Novo Holdings Merger: Attractive Spread

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Catalent, Inc. to Report Q2, 2024 Results on Feb 09, 2024

Catalent, Inc. Announces Executive Changes

Catalent, Inc., Annual General Meeting, Jan 25, 2024

Catalent: Debt Remains An Overhang

Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. to Report Q1, 2024 Results on Nov 15, 2023

Catalent Remains Overvalued

Catalent, Inc. Appoints David McErlane as Group President of Catalent’s Biologics segment, Effective September 25, 2023

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

Catalent, Inc. Appoints Steven Barg as A Member of the Board of Directors

Catalent, Inc. announced delayed annual 10-K filing

Full year 2023 earnings: EPS misses analyst expectations

Catalent, Inc. Announces Board Changes

Catalent, Inc. to Report Q4, 2023 Results on Aug 29, 2023

Calculating The Intrinsic Value Of Catalent, Inc. (NYSE:CTLT)

Insufficient new directors

Catalent, Inc. Announces Executive Changes

Catalent: Myriad Issues To Fix

Catalent, Inc.(NYSE:CTLT) dropped from Russell 1000 Growth Index

Catalent, Inc. Appoints Matti Masanovich as Senior Vice President, Effective July 5, 2023

Catalent Regains Compliance with NYSE Continued Listing Standards

Catalent, Inc. Reports Impairment Results for the Quarter Ended March 31, 2023

New minor risk - Earnings quality

Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023

Catalent, Inc. announced delayed 10-Q filing

Price target decreased by 7.6% to US$63.17

Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023

Now 30% undervalued after recent price drop

Catalent (NYSE:CTLT) Has A Somewhat Strained Balance Sheet

Insider recently sold US$72k worth of stock

Investor sentiment improves as stock rises 15%

Now 22% undervalued after recent price drop

Consensus EPS estimates fall by 10%

Investor sentiment deteriorates as stock falls 29%

A Look At The Intrinsic Value Of Catalent, Inc. (NYSE:CTLT)

Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary

Price target increased by 11% to US$82.36

Catalent, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Danaher Reportedly Expresses Takeover Interest in Catalent

Investor sentiment improves as stock rises 27%

Why did Catalent stock soar today? Potential takeover by Danaher

We Think Catalent (NYSE:CTLT) Is Taking Some Risk With Its Debt

Catalent, Inc. to Report Q2, 2023 Results on Feb 07, 2023

Catalent, Inc. Announces the Appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America

Catalent to make Sarepta Therapeutics' muscle wasting gene therapy under supply deal

An Intrinsic Calculation For Catalent, Inc. (NYSE:CTLT) Suggests It's 27% Undervalued

Humanigen to pay Catalent Pharma $12M to settle supply agreement dispute

Catalent, Inc. Announces Director Changes

Catalent falls after new short call from Glasshouse Research

Now 23% undervalued after recent price drop

Investor sentiment improved over the past week